Intravitreal devices for the treatment of vitreous inflammation

John B Christoforidis, Susie Chang, Angela Jiang, Jillian Wang, Colleen M. Cebulla

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of therapy. The use of implantable intravitreal devices for drug delivery is an emerging field in the treatment of vitreous inflammation as well as other ophthalmologic diseases. There are unique challenges in the design of these devices which include implants, polymers, and micro- and nanoparticles. This paper reviews current and investigational drug delivery systems for treating vitreous inflammation as well as other pathologic conditions that induce visual loss. The use of nonbiodegradable devices such as polyvinyl alcohol-ethylene vinyl acetate polymers and polysulfone capillary fibers, and biodegradable devices such as polylactic acid, polyglycolic acid, and polylactic-co-glycolic acid, polycaprolactones, and polyanhydrides are reviewed. Clinically used implantable devices for therapeutic agents including ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and dexamethasone are described. Finally, recently developed investigational particulate drug delivery systems in the form of liposomes, microspheres, and nanoparticles are examined.

Original languageEnglish (US)
Article number126463
JournalMediators of Inflammation
Volume2012
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Investigational Drugs
Inflammation
Equipment and Supplies
glycolic acid
Drug Delivery Systems
Nanoparticles
Polyanhydrides
Polymers
Fluocinolone Acetonide
Polyglycolic Acid
Equipment Design
Polyvinyl Alcohol
Triamcinolone Acetonide
Ganciclovir
Therapeutics
Microspheres
Liposomes
Dexamethasone
Pharmaceutical Preparations
ethylene

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Intravitreal devices for the treatment of vitreous inflammation. / Christoforidis, John B; Chang, Susie; Jiang, Angela; Wang, Jillian; Cebulla, Colleen M.

In: Mediators of Inflammation, Vol. 2012, 126463, 2012.

Research output: Contribution to journalArticle

Christoforidis, John B ; Chang, Susie ; Jiang, Angela ; Wang, Jillian ; Cebulla, Colleen M. / Intravitreal devices for the treatment of vitreous inflammation. In: Mediators of Inflammation. 2012 ; Vol. 2012.
@article{18c3a479031a433e940851745da12f65,
title = "Intravitreal devices for the treatment of vitreous inflammation",
abstract = "The eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of therapy. The use of implantable intravitreal devices for drug delivery is an emerging field in the treatment of vitreous inflammation as well as other ophthalmologic diseases. There are unique challenges in the design of these devices which include implants, polymers, and micro- and nanoparticles. This paper reviews current and investigational drug delivery systems for treating vitreous inflammation as well as other pathologic conditions that induce visual loss. The use of nonbiodegradable devices such as polyvinyl alcohol-ethylene vinyl acetate polymers and polysulfone capillary fibers, and biodegradable devices such as polylactic acid, polyglycolic acid, and polylactic-co-glycolic acid, polycaprolactones, and polyanhydrides are reviewed. Clinically used implantable devices for therapeutic agents including ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and dexamethasone are described. Finally, recently developed investigational particulate drug delivery systems in the form of liposomes, microspheres, and nanoparticles are examined.",
author = "Christoforidis, {John B} and Susie Chang and Angela Jiang and Jillian Wang and Cebulla, {Colleen M.}",
year = "2012",
doi = "10.1155/2012/126463",
language = "English (US)",
volume = "2012",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Intravitreal devices for the treatment of vitreous inflammation

AU - Christoforidis, John B

AU - Chang, Susie

AU - Jiang, Angela

AU - Wang, Jillian

AU - Cebulla, Colleen M.

PY - 2012

Y1 - 2012

N2 - The eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of therapy. The use of implantable intravitreal devices for drug delivery is an emerging field in the treatment of vitreous inflammation as well as other ophthalmologic diseases. There are unique challenges in the design of these devices which include implants, polymers, and micro- and nanoparticles. This paper reviews current and investigational drug delivery systems for treating vitreous inflammation as well as other pathologic conditions that induce visual loss. The use of nonbiodegradable devices such as polyvinyl alcohol-ethylene vinyl acetate polymers and polysulfone capillary fibers, and biodegradable devices such as polylactic acid, polyglycolic acid, and polylactic-co-glycolic acid, polycaprolactones, and polyanhydrides are reviewed. Clinically used implantable devices for therapeutic agents including ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and dexamethasone are described. Finally, recently developed investigational particulate drug delivery systems in the form of liposomes, microspheres, and nanoparticles are examined.

AB - The eye is a well-suited organ for local delivery of therapeutics to treat vitreous inflammation as well as other pathologic conditions that induce visual loss. Several conditions are particularly challenging to treat and often require chronic courses of therapy. The use of implantable intravitreal devices for drug delivery is an emerging field in the treatment of vitreous inflammation as well as other ophthalmologic diseases. There are unique challenges in the design of these devices which include implants, polymers, and micro- and nanoparticles. This paper reviews current and investigational drug delivery systems for treating vitreous inflammation as well as other pathologic conditions that induce visual loss. The use of nonbiodegradable devices such as polyvinyl alcohol-ethylene vinyl acetate polymers and polysulfone capillary fibers, and biodegradable devices such as polylactic acid, polyglycolic acid, and polylactic-co-glycolic acid, polycaprolactones, and polyanhydrides are reviewed. Clinically used implantable devices for therapeutic agents including ganciclovir, fluocinolone acetonide, triamcinolone acetonide, and dexamethasone are described. Finally, recently developed investigational particulate drug delivery systems in the form of liposomes, microspheres, and nanoparticles are examined.

UR - http://www.scopus.com/inward/record.url?scp=84867775167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867775167&partnerID=8YFLogxK

U2 - 10.1155/2012/126463

DO - 10.1155/2012/126463

M3 - Article

C2 - 22988344

AN - SCOPUS:84867775167

VL - 2012

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 126463

ER -